Inhaled Nitric Oxide (iNO) for Congenital Diaphragmatic Hernia (CDH) - The "NoNO Trial" - a Multi-center, De-implementation, Stepped-wedge, Cluster-randomized Trial Within an Established Collaborative

The purpose of this study is to Determine if deimplementation of iNO in the post-natal resuscitation/stabilization phase affects the composite outcome of ECLS use and/or mortality, as well as ECLS use, mortality, and/or oxygenation in CDH newborns and to establish the cost-effectiveness of deimplementing iNO as a therapy in the postnatal resuscitation/stabilization phase of CDH management, which will be assessed as the incremental health system costs (savings) per prevented ECLS use and/or death.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Texas Health Science Center at Houston

NCT04181359 / Not yet recruitingPhase 1/2IIT

The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.

Interstitial Lung Disease (ILD) is a is a lung disorder which makes breathing more difficult. During exercise, patients with ILD are not efficient breathers and this leads to serious breathing difficulties, which often causes these patients to stop exercise at low intensities. The investigators think that these patients with ILD have problems exchanging fresh gas (i.e., oxygen) into the blood stream because of poor lung blood vessel function. The investigators will test whether inhaled medications, specifically nitric oxide, can improve lung blood vessel function and decrease breathing difficulties during exercise. With this research, the investigators will understand more about breathing efficiency and lung blood vessel function in mild ILD patients, and find out whether improving lung blood vessel function helps ILD patients breathe easier and exercise longer. Understanding the reasons behind the feeling of difficult breathing may lead to more effective therapy and improved quality of life in ILD patients.

Start Date01 Sep 2024

Sponsor / Collaborator

University of Alberta

NCT05871606 / Not yet recruitingPhase 1IIT

Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Phase I Drug Pilot Research Plan

The purpose of this study is to determine the safety and feasibility of using inhaled nitric oxide (iNO) in patients undergoing intra-arterial mechanical thrombectomy (blood clot extraction or IAMT) for treatment of acute ischemic (non-bleeding) stroke (AIS).

Start Date01 Jun 2024

Sponsor / Collaborator

Wake Forest School of Medicine

100 Clinical Results associated with Nitric oxide (inhaled)

100 Translational Medicine associated with Nitric oxide (inhaled)

100 Patents (Medical) associated with Nitric oxide (inhaled)

3,644

Literatures (Medical) associated with Nitric oxide (inhaled)

01 Jun 2024·Toxicology Reports

Causes of acquired methemoglobinemia – A retrospective study at a large academic hospital

Article

Author: Krasowski, Matthew D ; Belzer, Alex

Methemoglobinemia is a potentially life-threatening condition caused by the formation of methemoglobin, a form of hemoglobin that cannot bind oxygen. While there are some rare congenital causes of methemoglobinemia, most cases are acquired from the effects of specific drugs or environmental exposures. In this retrospective study, we analyzed a large data set of whole blood samples analyzed for methemoglobin at an academic medical center in Midwestern United States that provides both pediatric and adult services. For a 14 year timeframe (May 2009- June 2023), we performed detailed chart analysis of all patients with a methemoglobin concentration of 3.1 % or higher. For an earlier 13 year timeframe (January 1996-April 2009), we performed chart review for all patients with a methemoglobin concentration of 10.0 % or higher. For the 2009-2023 data, dapsone was the most frequent cause of methemoglobinemia (methemoglobin 3.1 % or higher) in both pediatric (73.3 %, 115 clinical encounters, 105 unique patients) and adult (65.3 %, 195 clinical encounters, 190 unique patients) populations. Inhaled nitric oxide as medical therapy was the next most frequent cause in both pediatric (18.1 %) and adult (13.2 %) populations. Causes associated with two or more unique episodes with methemoglobin concentrations of 10.0 % and higher included the following: dapsone (n = 40 episodes), benzocaine (n = 10), recreational use of amyl or isobutyl nitrite (n = 3), suicide attempt with sodium nitrite (n = 3 with 1 fatality; all 3 cases within last 3 years), food contaminated with nitrates (n = 2), and sepsis (n = 2). A total of 18 patients received treatment with methylene blue including 5 cases associated with benzocaine and all of the cases associated with amyl nitrite, isobutyl nitrite, sodium nitrite, and contaminated food. Only 3 patients with dapsone-associated methemoglobinemia received methylene blue, reflecting primary management by dose reduction or discontinuation of drug. Overall, our data reinforce previous studies showing dapsone, inhaled nitric oxide, and nitrites as common agents causing methemoglobinemia in a patient population seen at a medical center. Our data also are consistent with recent epidemiology trends showing increase in suicide attempts using sodium nitrite.

01 May 2024·Acta Paediatrica

Transient abnormal myelopoiesis requiring advanced neonatal intensive care treatment

Article

Author: Seager, Emilie ; Chalia, Maria ; Hannam, Simon ; Rao, Anupama

AbstractAimFive to thirty percent of neonates with trisomy 21 develop transient abnormal myelopoiesis (TAM) with a high mortality rate. The aim of the study was to identify contributing factors that determine mortality and need for chemotherapy in this patient group.MethodsSix‐year, single‐centre, retrospective study of neonatal TAM cases requiring admission to intensive care. Data were collected from electronic patient records, laboratory and genetic results. The odds ratio was calculated to assess the likelihood of neonates with certain clinical characteristics having short‐term mortality and needing chemotherapy.ResultsTwenty‐one neonates were studied with a mortality rate of 28%. Neonates requiring inotropic support (OR 19, 95% CI: 0.9–399, p = 0.05) and inhaled nitric oxide (iNO) (OR 13, 95% CI: 1.4–124.3, p = 0.03) were less likely to survive to discharge. Neonates needing mechanical ventilation (OR 14, 95% CI: 1.1–185.5, p = 0.04), or a white cell count >50 × 109/L (OR 27, 95% CI: 1.2–605.7, p = 0.04) were more likely to receive chemotherapy.ConclusionA high mortality rate was identified in TAM neonates with symptomatic pulmonary hypertension (PH) needing active treatment strategies, such as inotropes and iNO. The presence of PH should be considered in the clinical management, prognosis and parental counselling.

01 May 2024·General Thoracic and Cardiovascular Surgery

Real-world safety and effectiveness of inhaled nitric oxide therapy for pulmonary hypertension during the perioperative period of cardiac surgery: a post-marketing study of 2817 patients in Japan

Article

Author: Matsugi, Emi ; Kobayashi, Tomomi ; Okayasu, Motohiro ; Takashima, Shigeki ; Doteguchi, Shuhei

AbstractObjectiveTo evaluate the real-world safety and effectiveness of inhaled nitric oxide (INOflo® for Inhalation 800 ppm) for perioperative pulmonary hypertension associated with cardiac surgery in Japan.MethodsThis was a prospective, non-interventional, all-case, post-marketing study of pediatric and adult patients who received perioperative INOflo with cardiac surgery from November 2015–December 2020. Safety and effectiveness were monitored from INOflo initiation to 48 h after treatment completion or withdrawal. Safety outcomes included adverse drug reactions, blood methemoglobin concentrations, and inspired nitrogen dioxide concentrations over time. Effectiveness outcomes included changes in central venous pressure among pediatrics, mean pulmonary arterial pressure among adults, and the partial pressure of arterial oxygen/fraction of inspired oxygen ratio (PaO2/FiO2) in both populations.ResultsThe safety analysis population included 2,817 Japanese patients registered from 253 clinical sites (pediatrics, n = 1375; adults, n = 1442). INOflo was generally well tolerated; 15 and 20 adverse drug reactions were reported in 14 pediatrics (1.0%) and 18 adults (1.2%), respectively. No clinically significant elevations in blood methemoglobin and inspired nitrogen dioxide concentrations were observed. INOflo treatment was associated with significant reductions in both central venous pressure among pediatrics and mean pulmonary arterial pressure among adults, and significant improvements in PaO2/FiO2 among pediatrics and adults with PaO2/FiO2 ≤ 200 at baseline.ConclusionsPerioperative INOflo treatment was a safe and effective strategy to improve hemodynamics and oxygenation in patients with pulmonary hypertension during cardiac surgery. These data support the use of INOflo for this indication in Japanese clinical practice.

News (Medical) associated with Nitric oxide (inhaled)

27 Feb 2024

·www.biospace.com

Third Pole Therapeutics Announces Successful Completion of Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery System

WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Third Pole Therapeutics, a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and infectious diseases, announced today the successful completion of an early feasibility study (EFS) performed under an Investigational Device Exemption granted by the FDA. This study evaluated eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD). “The successful completion of our EFS which validated the safe and practical use of our eNOfit™ system, enables us to confidently move into larger randomized placebo-controlled safety and efficacy studies. This is a significant milestone for Third Pole and a major step forward in validating the delivery of iNO for home and travel use, to improve the quality of life of the millions of patients suffering from PH due to chronic lung diseases like ILD and COPD. Importantly, this value creating milestone will trigger the final funding of Third Pole’s Series B investment round.” said Bill Athenson, CEO of Third Pole. “In addition to Third Pole’s eNOcare™ device, in development to increase access and affordability of nitric oxide for in hospital use, the eNOfit™ device is a two-pound, portable NO generation and delivery device for outpatient use. There is a significant need for new ways to treat patients living with PH-ILD and PH-COPD outside the hospital. We look forward to acquiring the clinical data to support the use of eNOfit™ in at-home and ambulatory settings from Third Pole’s upcoming trials. The trials are expected to confirm that the same clinical benefits of nitric oxide in PH observed over the last 30 years in hospitalized patients, can be achieved in out-of-hospital patients as well", said Dr. Rajan Saggar, Professor of Medicine, Director Pulmonary Hypertension Program, Co-Director Pulmonary Vascular Disease Program, Lung & Heart-Lung Transplant and Pulmonary Hypertension Programs, David Geffen School of Medicine, UCLA. The Group 3 Pulmonary Hypertension cohort includes ILD and COPD patients with PH 1,2. In healthy people, deoxygenated blood returning to the heart from all organs and tissues is pumped by the right heart through the pulmonary arteries into the lungs. Within the lungs, the pulmonary arteries divide into smaller vessels to take in oxygen and remove carbon dioxide in the air sacs (alveoli). The oxygen-rich blood then returns to the left side of the heart, where it is pumped back to organs and tissues. Normally, the blood flows easily through the pulmonary arteries, but in PH, the arteries become stiff, damaged, and narrow. This makes blood flow much more difficult and causes the blood pressure in the lungs to rise (PH) and the right heart to work harder. Over time, the right heart can fail, leading to a poor prognosis and death. Patients with Group 3 PH-ILD suffer from shortness of breath, fatigue, and fainting episodes. They have a difficult time doing normal chores and must take breaks while doing activities of daily living. As their disease advances, they are often dependent on supplemental oxygen to maintain adequate oxygenation levels at rest and on exertion. Inhaled nitric oxide relaxes smooth muscle within the pulmonary vasculature, increasing the diameter of pulmonary arteries and decreasing their resistance to blood flow. Inhaled nitric oxide has been shown in the clinic to reduce the load on the right heart but this benefit has yet to be demonstrated in patients outside the hospital. About Third Pole Therapeutics Third Pole Therapeutics develops and delivers critical life-sustaining cardiopulmonary therapies. Warren Zapol, M.D., Third Pole's founder, invented the first use for iNO for the treatment of persistent pulmonary hypertension in new-born infants (blue babies). Since then, in addition to blue babies, hundreds of thousands of pediatric and adult patients experiencing elevated pulmonary pressure, inflammation, and poor oxygenation during and after heart surgery have been treated with inhaled nitric oxide, creating a $600 million iNO industry, concentrated in large hospitals and developed markets. Two decades later, Third Pole has successfully created a scalable technology that generates and delivers NO for inhalation, instantly, on-demand, and in unlimited quantities. Last year, Third Pole announced an agreement for a $32M strategic equity investment to accelerate the development of its tankless iNO platform from one of the largest healthcare companies in the world to enhance their product offering in the cardiopulmonary device market. Third Pole was chosen as “best in class” technology that will solve the cost and logistical hurdles which have prevented widespread iNO use in various markets in the U.S. and abroad that lacked the training and infrastructure required to transport, maintain, return, and refill large cylinders of compressed gas safely. Third Pole's two innovative platforms include eNOfit™, a miniaturized wearable device for home and travel and eNOcare™, a lightweight portable in-hospital device. Both make NO by combining electricity and ambient air, creating a "make it and take it" therapy, free from the hazards of compressed gas storage. These broadly patented, versatile platforms and derivative products have the potential to rapidly capture the entire existing tank-based market and expand beyond current indications to treat interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, heart failure, stroke, and life threatening, refractory viral and bacterial infections. For more information, please visit . Third Pole’s product development has been generously supported by awards from the National Heart, Lung, and Blood Institute of the National Institutes of Health and the National Center for Advancing Translational Sciences of the National Institutes of Health. Contact: Third Pole Therapeutics Elizabeth Holmberg, Chief Financial Officer 908-310-0596 eholmberg@pole3.com

11 Dec 2023

·www.globenewswire.com

Third Pole Therapeutics Announces First Patient Dosed in Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery System

Data from Study Anticipated in Q1 2024WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Third Pole Therapeutics, Inc., a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and infectious diseases, today announced that the first patient has been dosed in an early feasibility study (EFS) performed under an Investigational Device Exemption granted by the FDA. This study is evaluating eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD). “We are excited to bring our eNOfit™ device to the clinic for the first time with the initiation of this study. We have designed this study to validate the safe and practical use of our eNOfit™ system prior to moving into a larger randomized placebo-controlled safety and efficacy study in 2024. This is a significant milestone for Third Pole and a major step forward in validating the delivery of iNO for home and travel use, to improve the quality of life of the millions of patients suffering from PH due to chronic lung diseases like ILD and COPD,” said Bill Athenson, CEO of Third Pole. “There is a significant need for new ways to treat patients living with PH-ILD and PH-COPD outside the hospital. We look forward to seeing the emerging clinical data supporting eNOfit™ in at-home and ambulatory settings from these trials, which should confirm the clinical benefits of nitric oxide on PH observed over the last 30 years in hospitalized patients", said Dr. Rajan Saggar, Professor of Medicine, Director Pulmonary Hypertension Program, Co-Director Pulmonary Vascular Disease Program, Lung & Heart-Lung Transplant and Pulmonary Hypertension Programs, David Geffen School of Medicine, UCLA. About Group 3 Pulmonary Hypertension (includes ILD and COPD patients with PH)1,2 In healthy people, deoxygenated venous blood returning to the heart from all body organs and tissues travels from the right heart through the pulmonary arteries into the lungs. Within the lungs, the pulmonary arteries divide into smaller vessels to take in oxygen and remove carbon dioxide in the air sacs (alveoli). The oxygen-rich blood then returns to the left side of the heart from where it is pumped back to body organs and tissues. Normally, the blood flows relatively easily through the pulmonary arteries, but in PH, the arteries become stiff, damaged, and narrow. This makes blood flow much more difficult and causes the blood pressure in the lungs to rise (PH) and the right heart to work harder. Over time, the right heart can fail, leading to a poor prognosis and death. Patients with Group 3 PH-ILD suffer from shortness of breath, fatigue, and fainting episodes. They have a difficult time doing normal chores and must take breaks while doing activities of daily living. As their disease advances, they are often dependent on supplemental oxygen to maintain adequate oxygenation levels at rest and on exertion. 1. https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-hypertension 2. https://pulmonaryhypertensionrn.com/functional-classification-of-pulmonary-arterial-hypertension-pah/ About Third Pole Therapeutics Third Pole Therapeutics develops and delivers critical life-sustaining cardiopulmonary therapies. Warren Zapol, M.D., Third Pole's founder, invented the first use for iNO for the treatment of hypoxic respiratory failure in new-born infants (blue babies). Since then, in addition to blue babies, hundreds of thousands of pediatric and adult patients experiencing elevated pulmonary pressure, inflammation, and poor oxygenation during and after heart surgery have been treated with inhaled nitric oxide, creating a $600 million inhaled NO industry, concentrated in large hospitals and developed markets. Two decades later, Third Pole has successfully created a scalable technology that generates and delivers NO for inhalation, instantly, on-demand, and in unlimited quantities. Third Pole's technology solves the cost and logistical hurdles which have prevented widespread iNO use in various markets in the U.S. and abroad that lacked the training and infrastructure required to transport, maintain, return, and refill large cylinders of compressed gas safely. Third Pole's two novel platforms include eNOfit™, a miniaturized wearable device for home and travel and eNOcare™, a lightweight portable in-hospital device. Both make NO by combining electricity and ambient air, creating a "make it and take it" therapy, free from the hazards of compressed gas storage. These broadly patented, versatile platforms and derivative products have the potential to rapidly capture the entire existing tank-based market and expand beyond current indications to treat interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, heart failure, stroke, and life threatening, refractory viral and bacterial infections. For more information, please visit www.pole3.com. Third Pole’s product development has been generously supported by awards from the National Heart, Lung, and Blood Institute of the National Institutes of Health and the National Center for Advancing Translational Sciences of the National Institutes of Health. Third Pole TherapeuticsElizabeth Holmberg, Chief Financial Officer908-310-0596eholmberg@pole3.com

Clinical Study

11 Dec 2023

·www.biospace.com

Third Pole Therapeutics Announces First Patient Dosed in Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery SystemData from Study Anticipated in Q1 2024

WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Third Pole Therapeutics, Inc., a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and infectious diseases, today announced that the first patient has been dosed in an early feasibility study (EFS) performed under an Investigational Device Exemption granted by the FDA. This study is evaluating eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD). “We are excited to bring our eNOfit™ device to the clinic for the first time with the initiation of this study. We have designed this study to validate the safe and practical use of our eNOfit™ system prior to moving into a larger randomized placebo-controlled safety and efficacy study in 2024. This is a significant milestone for Third Pole and a major step forward in validating the delivery of iNO for home and travel use, to improve the quality of life of the millions of patients suffering from PH due to chronic lung diseases like ILD and COPD,” said Bill Athenson, CEO of Third Pole. “There is a significant need for new ways to treat patients living with PH-ILD and PH-COPD outside the hospital. We look forward to seeing the emerging clinical data supporting eNOfit™ in at-home and ambulatory settings from these trials, which should confirm the clinical benefits of nitric oxide on PH observed over the last 30 years in hospitalized patients", said Dr. Rajan Saggar, Professor of Medicine, Director Pulmonary Hypertension Program, Co-Director Pulmonary Vascular Disease Program, Lung & Heart-Lung Transplant and Pulmonary Hypertension Programs, David Geffen School of Medicine, UCLA. About Group 3 Pulmonary Hypertension (includes ILD and COPD patients with PH)1,2 In healthy people, deoxygenated venous blood returning to the heart from all body organs and tissues travels from the right heart through the pulmonary arteries into the lungs. Within the lungs, the pulmonary arteries divide into smaller vessels to take in oxygen and remove carbon dioxide in the air sacs (alveoli). The oxygen-rich blood then returns to the left side of the heart from where it is pumped back to body organs and tissues. Normally, the blood flows relatively easily through the pulmonary arteries, but in PH, the arteries become stiff, damaged, and narrow. This makes blood flow much more difficult and causes the blood pressure in the lungs to rise (PH) and the right heart to work harder. Over time, the right heart can fail, leading to a poor prognosis and death. Patients with Group 3 PH-ILD suffer from shortness of breath, fatigue, and fainting episodes. They have a difficult time doing normal chores and must take breaks while doing activities of daily living. As their disease advances, they are often dependent on supplemental oxygen to maintain adequate oxygenation levels at rest and on exertion. 1. 2. About Third Pole Therapeutics Third Pole Therapeutics develops and delivers critical life-sustaining cardiopulmonary therapies. Warren Zapol, M.D., Third Pole's founder, invented the first use for iNO for the treatment of hypoxic respiratory failure in new-born infants (blue babies). Since then, in addition to blue babies, hundreds of thousands of pediatric and adult patients experiencing elevated pulmonary pressure, inflammation, and poor oxygenation during and after heart surgery have been treated with inhaled nitric oxide, creating a $600 million inhaled NO industry, concentrated in large hospitals and developed markets. Two decades later, Third Pole has successfully created a scalable technology that generates and delivers NO for inhalation, instantly, on-demand, and in unlimited quantities. Third Pole's technology solves the cost and logistical hurdles which have prevented widespread iNO use in various markets in the U.S. and abroad that lacked the training and infrastructure required to transport, maintain, return, and refill large cylinders of compressed gas safely. Third Pole's two novel platforms include eNOfit™, a miniaturized wearable device for home and travel and eNOcare™, a lightweight portable in-hospital device. Both make NO by combining electricity and ambient air, creating a "make it and take it" therapy, free from the hazards of compressed gas storage. These broadly patented, versatile platforms and derivative products have the potential to rapidly capture the entire existing tank-based market and expand beyond current indications to treat interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, heart failure, stroke, and life threatening, refractory viral and bacterial infections. For more information, please visit . Third Pole’s product development has been generously supported by awards from the National Heart, Lung, and Blood Institute of the National Institutes of Health and the National Center for Advancing Translational Sciences of the National Institutes of Health. Third Pole Therapeutics Elizabeth Holmberg, Chief Financial Officer 908-310-0596 eholmberg@pole3.com

Clinical Study

100 Deals associated with Nitric oxide (inhaled)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
COVID-19	IN	SaNOtize Research & Development Corp.Startup	09 Feb 2022
Pulmonary Arterial Hypertension	JP	AIR WATER MEDICAL INC	16 Jul 2008
Hypertension, Pulmonary	IS	Linde Healthcare AB	01 Aug 2001
Hypertension, Pulmonary	EU	Linde Healthcare AB	01 Aug 2001
Hypertension, Pulmonary	NO	Linde Healthcare AB	01 Aug 2001
Hypertension, Pulmonary	LI	Linde Healthcare AB	01 Aug 2001
Neonatal respiratory failure	NO	Linde Healthcare AB	01 Aug 2001
Neonatal respiratory failure	IS	Linde Healthcare AB	01 Aug 2001
Neonatal respiratory failure	LI	Linde Healthcare AB	01 Aug 2001
Neonatal respiratory failure	EU	Linde Healthcare AB	01 Aug 2001
Respiratory Insufficiency	US	MALLINCKRODT HOSP PRODUCTS IP LTD	23 Dec 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	LK	SaNOtize Research & Development Corp.Startup	20 Nov 2021
COVID-19	Phase 3	CA	SaNOtize Research & Development Corp.Startup	20 Nov 2021
Sinusitis	Phase 2	CA	SaNOtize Research & Development Corp.Startup	13 Feb 2024
Diabetic foot ulcer	Phase 1	US	NOxy Health Products, LLC	15 May 2024
Oropharyngeal candidiasis	Phase 1	CA	SaNOtize Research & Development Corp.Startup	20 Jan 2024
Pulmonary Disease, Chronic Obstructive	Phase 1	CA	Queen's University	01 Sep 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2023	Phase 2	refractory acute lymphoid leukemia in relapse Consolidation	110	mini-HCVD + InO	cvwejualzk(avglpfskch) = ywottrawox vxgclwojmb (qzcedkcgvv ) View more	-	08 Jun 2023
				mini-HCVD + InO + blina	cvwejualzk(avglpfskch) = gokhqtiloz vxgclwojmb (qzcedkcgvv ) View more
EHA2022	Not Applicable	Refractory B Acute Lymphoblastic Leukemia	65	INO and Blina	(evrarajjvg) = wimxebjnxj psfkuozcbj (dzqgwcuoyw ) View more	-	12 May 2022
O131 (EBMT2023)	Not Applicable	Pre B-cell acute lymphoblastic leukemia	51	Blina	(npxbpzjgid) = sqvqskjqcd zdohjoahnf (rsdiieuyuh ) View more	Positive	23 Apr 2023
				Ino	(npxbpzjgid) = ccukoxalmb zdohjoahnf (rsdiieuyuh ) View more
Pubmed Manual	Phase 3	COVID-19	306	NONS	guqbkptguo(jjavdynfpa): difference = -0.52 (95% CI, -0.92 to -0.12) View more	Positive	29 Jun 2022
				placebo
ERS2018	Not Applicable	Pulmonary Disease, Chronic Obstructive \| Hypertension, Pulmonary	10	Pulsed inhaled nitric oxide (iNO)	ulradnfgph(ntczzztcjl) = mihkzwltkc esxkzhnqdu (gekbvtfavk )	Positive	15 Sep 2018
				Long-term oxygen therapy (LTOT)	(vodnmleinw) = fgafmcpwbu lnztkhtnfd (uvignhnvoc )
NCT01802619 (Pubmed \| Anesth Analg)	Phase 1/2	Acute Kidney Injury free hemoglobin	110	Nitric oxide	(blpzhvnwky) = gmfvrjaokm gojgfqgsqn (khvzlwcycm ) View more	-	01 Jun 2021
				Nitrogen	(hielnajpcq) = fgpgoptlcp wucmkvqowj (ydiipricqh )
NCT03081052 (Pubmed)	Phase 4	-	231	Inhaled Epoprostenol	vlpamelgyr(cpkegzvwef) = zmbatibyal rblxcfuujj (polpydjxhq )	-	04 Jul 2023
				Nitric Oxide	vlpamelgyr(cpkegzvwef) = hddgxlyxmr rblxcfuujj (polpydjxhq )
NCT04134078 (Pubmed \| Nitric Oxide)	Early Phase 1	Heart Arrest	20	Inhaled Nitric Oxide	xqueuantqb(iziyorrtqz) = bcgckmmkwz biyqjujlsc (iaxjczjfft ) View more	-	03 Jul 2021
				Inhaled Nitric Oxide (Standard care)	xqueuantqb(iziyorrtqz) = ihwhunmwwt biyqjujlsc (iaxjczjfft ) View more
NCT04290871 (Pubmed)	Phase 2	COVID-19	815	Inhaled nitric oxide (iNO)	(lsorlpxtzt): OR = 2.35 (95% CI, 1.3 - 4.26) View more	Positive	03 Oct 2022
				No inhaled nitric oxide (iNO)
ESC2019	Not Applicable	Heart Failure	26	Levosimendan	evqchjtagr(iakzueooug) = nyzhodiojt ylvbajwbcw (hnvnsnaydc ) View more	-	01 Sep 2019
				Nitric oxide	evqchjtagr(iakzueooug) = fkkzxqvcoe ylvbajwbcw (hnvnsnaydc ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nitric oxide (inhaled)

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation